Amgen Mexico – Elvin Penn, Executive Director & General Manager
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact details
Ave. Vasco de Quiroga 3000 piso 4
Col. Santa Fe, Del. Alvaro Obregón
CP 01210 México DF
MEXICO
Tel. +52 (55) 4424 4600
www.amgen.mx
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
Ricardo Amtmann, President at Laboratorios Sanfer, explains how they have grown their business by 100 percent throughout the last three years and showcases the added value of Sanfer to patients…
Patricia López, general manager at seca Mexico, showcases the added value of seca’s product portfolio and explains that interconnectivity should be medical devices’ path of development; generating benefits for patients,…
Patrick Troop, CEO at Pharma Tycsa, explains the company’s unique business approach in Mexico developing “clinical pharmacies” model to address chronic diseases treatment in the points of care and the…
Victor Manuel Fernández Navarro, CEO at Vicma, explains how strategically important is to have a healthy business model in the distribution industry through sustainable collection period, attractive profit margins and…
Dr. Marco A. Martinez Rios, General Director of the National Institute of Cardiology in Mexico elaborates on the institution’s rich history in Mexico and its contributions to cardiology through research,…
Andrés Matesanz, general manager at DCS Pharma Mexico, explains how the merger between Dolder and Chemswiss has enlarged the capabilities and the offering of the company in Mexico and showcases…
José Alberto Peña, managing director at Marzam Mexico, showcases the benefits that distributors can offer to the healthcare and life science sector as well as Marzam’s strategy to overcome the…
Carlos Pérez Muguía, CEO at NYCE, showcases the increasing added value brought by this leading Cofepris’ authorized third party (ATP) to the healthcare industry, the future objectives of the company…
Alan Smithers, CEO at IFA Celtics, highlights the obesity as a national healthcare challenge and explains the company’s strategy to enlarge its capabilities to cope with the increasing needs of…
Salomon Rayek, CEO at Sinbiotik, explains how the company managed to adapt its business model to the industry trends and showcases the added value of Sinbiotik when offering high quality,…
Due to economic necessity, the Mexican government is attempting to slash annual spending; an act that could have serious consequences on the country’s ability to provide its citizens with healthcare.…
Francisco Rodriguez, general manager Mexico and Latin America at Mundipharma, provides an overview of the customized market approach that has allowed the company to establish itself as the partner of…
See our Cookie Privacy Policy Here
